Fig1. In vivo efficacy evaluation of anti-IL23 and anti-IL23/IL12 in imiquimod (IMQ)-induced psoriasis model in hIL23A/hIL12B mice (3-6 mice/group, 6 weeks, female). 

IMQ treatment induced body weight loss in female hIL-23A/hIL-12B mice. Neither Risankizumab nor Ustekinumab treatment alleviated this weight loss, with both antibody-treated groups showing final body weight reductions.

Fig2. In vivo efficacy evaluation of anti-IL23 and anti-IL23/IL12 in imiquimod (IMQ)-induced psoriasis model in hIL23A/hIL12B mice (3-6 mice/group, 6 weeks, female).

IMQ treatment successfully induced psoriasis-like skin inflammation in female hIL-23A/hIL-12B mice, characterized by increased skin thickness and elevated PASI scores (including erythema and scaling) over the 7-day observation period. Notably, Risankizumab demonstrated better therapeutic effect than Ustekinumab in lleviating IMQ-induced psoriasis.

Fig3.H&E staining of psoriatic skin lesions in IMQ-induced mice. Compared to the control group (A) , all IMQ-treated groups displayed skin thickening. The IMQ+Vehicle (B) and IMQ+Ustekinumab (D) groups showed progressive and plaque-stage psoriasis symptoms focal parakeratosis, spongiosis, twisted and dilated capillaries (Black), and lymphocytic infiltration in the dermal papillae (Red), whereas the IMQ+Risankizumab group (C) showed reduced epidermal thickness and ameliorated histopathological features. Scale bar = [500] µm.

IMQ treatment induced significant psoriasis-like skin thickening and histopathological features, including parakeratosis, spongiosis, dilated capillaries, and lymphocytic infiltration, as seen in the IMQ induced groups. Comparing to Ustekinumab, Risankizumab treatment significantly alleviated these psoriatic symptoms and reduced epidermal thickness, demonstrating its therapeutic effect in this IMQ-induced psoriasis model.